Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia

@article{Sabatowski2012SafetyAE,
  title={Safety and efficacy outcomes of long-term treatment up to 4 years with 5\% lidocaine medicated plaster in patients with post-herpetic neuralgia},
  author={Rainer Sabatowski and Guy H Hans and Ingrid Tacken and Sofia Kapanadze and Bettina Buchheister and Ralf Baron},
  journal={Current Medical Research and Opinion},
  year={2012},
  volume={28},
  pages={1337 - 1346}
}
Abstract Objective: Prospective evaluation of the long-term efficacy and safety of the 5% lidocaine medicated plaster in patients with post-herpetic neuralgia (PHN). Research design and methods: Patients with persisting pain for ≥3 months after acute herpes zoster and a baseline pain intensity of at least 4 on an 11-point numerical rating scale (NRS 0–10) were treated with 5% lidocaine medicated plasters for up to 5 years and monitored in regular intervals. Efficacy parameters are presented for… 
View on Taylor & Francis
formsus.datasus.gov.br
31 Citations
Background Citations
10
Methods Citations
2

31 Citations

Citation Type

Citation Type

Treatment of postherpetic neuralgia with 5% lidocaine medicated plaster in elderly patients – subgroup analyses from three European clinical trials
TLDR
The 5% lidocaine medicated plaster provided pain relief and marked reductions in allodynia severity in elderly PHN patients with an excellent safety profile under short- and long-term treatment supporting the addition of the plaster to the treatment armamentarium for this age group.
Treatment of localized neuropathic pain of different etiologies with the 5% lidocaine medicated plaster – a case series
TLDR
Topical treatment with the 5% lidocaine medicated plaster was associated with effective pain relief and was well tolerated and Stratification by pain diagnosis showed marked improvements in overall pain intensity for patients with dorsalgia or postoperative/posttraumatic pain.
Lidocaine 700 mg medicated plaster for postherpetic neuralgia: real-world data from the German Pain e-Registry.
TLDR
Real-world data confirm the effectiveness and good tolerability of LMP under routine medical care, which was significantly more effective when compared with first-line oral systemic medications.
Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: a case series
TLDR
Observations confirm the effectiveness of lidocaine plasters in the treatment of PHN, indicating that 5% lidocane medicated plaster could reduce the size of the painful area.
The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence
TLDR
Although further well-controlled studies are warranted, the 5% lidocaine medicated plaster is efficacious and safe in LNP and may have particular clinical benefit in elderly and/or medically compromised patients because of the low incidence of adverse events.
5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability
TLDR
The 5% lidocaine medicated plaster provides a safe alternative to systemic medications for PHN treatment, including long-term pain treatment, and is better tolerated than systemic treatment with pregabalin.
Impact of topical 5% lidocaine-medicated plasters on sleep and quality of life in patients with postherpetic neuralgia.
TLDR
5% lidocaine-medicated plasters provide benefits beyond pain relief for patients with postherpetic neuralgia, and their perception of quality of life was improved.
Comparative Benefit–Risk Assessment for Lidocaine 700 mg Medicated Plaster and Pregabalin in Peripheral Neuropathic Pain Following a Structured Framework Approach
TLDR
Guided by the opinion of patients regarding key benefits and risks deemed important for treatments of peripheral neuropathic pain, an analysis showed that lidocaine 700 mg medicated plaster has a more favorable benefit–risk balance compared to pregabalin.
The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use
TLDR
The positioning of the 5% lidocaine-medicated plaster in international treatment guidelines is considered and how it may be influenced by the specific criteria used in developing them, such as the methodology employed by randomized, placebo-controlled trials.
Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?
TLDR
Findings provide a first assessment of the likelihood of treatment benefits with 5% lidocaine-medicated plaster in the management of cancer pain with neuropathic components and trigeminal neuropathic pain and support conducting large, well-designed multicenter studies.
...
1
2
3
4
...

References

SHOWING 1-10 OF 24 REFERENCES
Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study.
TLDR
It is suggested that long-term treatment with the 5% lidocaine medicated plaster may provide substantial and maintained reductions in pain intensity, and that it is continuously well tolerated in patients suffering from peripheral neuropathic pain associated with previous herpes zoster infection.
Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial.
TLDR
The lidocaine patch 5% should be considered a first-line therapy, alone or in combination with other agents, for PHN due to its efficacy, safety, minimal systemic side effects and drug interactions, and ease of administration.
Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster
TLDR
The 5% lidocaine medicated plaster provides sustained pain relief over long-term treatment in patients with neuropathic pain of various causes and is well tolerated.
Topical 5 % Lidocaine ( Lignocaine ) Medicated Plaster Treatment for PostHerpetic Neuralgia Results of a Double-Blind , Placebo-Controlled , Multinational Efficacy and Safety Trial
TLDR
This was a double-blind, placebo plaster-controlled, parallel-group, multicentre study employing enriched enrolment with randomized withdrawal methodology to evaluate the analgesic efficacy and safety of topical analgesic treatment compared with placebo plaster in patients with Post-herpetic neuralgia.
Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study
TLDR
It is suggested that 5% lidocaine medicated plaster is at least as effective as pregabalin for pain relief in PHN, with a favourable safety profile and a resulting positive benefit-risk ratio.
Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study
Analgesic Effect of Lidocaine Patch 5% in the Treatment of Acute Herpes Zoster: A Double‐Blind and Vehicle‐Controlled Study
Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia
Impact of herpes zoster and post-herpetic neuralgia on patients’ quality of life: a patient-reported outcomes survey
TLDR
HZ causes substantial pain, which seriously interferes with many aspects of daily life, particularly in patients with PHN, and PHN was associated with significantly worse outcomes than HZ.
I.V. ropivacaine compared with lidocaine for the treatment of tinnitus.
TLDR
Temporary clinically significant alleviation of tinnitus was observed only in a few individuals after both i.v. ropivacaine and lidocaine infusion, and the toxicity of ropavacaine limits its usefulness.
...
1
2
3
...